Daicel (4202) Q4 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2026 earnings summary
17 Jun, 2026Executive summary
Net sales for FY2026/3 were ¥579.6 billion, down 1.2% year-over-year, with operating income at ¥42.1 billion, down 31.0%, and profit attributable to owners of parent at ¥10.2 billion, down 79.4%, mainly due to impairment losses at the new COC resin plant.
EBITDA declined 16.6% to ¥85.4 billion, and comprehensive income was ¥27,343 million, down 11.6% year-over-year.
FY2027/3 forecasts project net sales of ¥595.0 billion (+2.7% YoY), operating income of ¥42.5 billion (+1.0%), and profit attributable to owners of parent of ¥32.0 billion (+214.3%).
The global economy showed gradual recovery, but uncertainty persisted due to geopolitical risks and sluggish conditions in China.
Financial highlights
ROE dropped to 2.8% (from 13.8%), and ROIC to 4.2% (from 6.1%) in FY2026/3.
EPS fell to ¥38.75 from ¥181.44 year-over-year.
Cash flows from operating activities decreased to ¥67.8 billion, with free cash flow at ¥20.1 billion.
Annual dividend maintained at ¥60 per share; 10.09 million shares repurchased for ¥13.7–13.8 billion.
Operating profit margin fell to 7.3% from 10.4% year-over-year.
Outlook and guidance
FY2027/3 expects recovery in profit due to absence of impairment losses and improved segment performance, despite ongoing raw material cost pressures.
Dividend policy for FY2027/3 to be announced with the new mid-term strategy.
Revenue growth driven by higher sales in engineering plastics and automotive inflators; operating profit to rise slightly, but ordinary income to decline due to lower dividend income and equity method profits.
Latest events from Daicel
- Operating income fell 25% year-over-year, but healthcare and mobility segments grew.4202
Q1 202617 Jun 2026 - Strong 1H growth driven by plastics and Smart segment, but full-year net income guidance cut.4202
Q2 202517 Jun 2026 - Sales and profits fell on FX and global headwinds, but cost controls lifted select segment margins.4202
Q2 202617 Jun 2026 - Operating profit nearly doubled on strong demand and favorable exchange rates.4202
Q1 202517 Jun 2026 - Sales rose 5.1%, but profits declined; FY2026 outlook: higher sales, lower profits, stable dividends.4202
Q4 202517 Jun 2026 - Net sales up 4.4% year-over-year, but profit margins declined amid mixed segment results.4202
Q3 202517 Jun 2026 - Profits fell on lower sales, but healthcare and safety segments showed strong growth.4202
Q3 202617 Jun 2026